136 related articles for article (PubMed ID: 36239491)
1. EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16.
Wang P; Xu L; Fan Y; Li B; Chen P; Zhang X; Sun Y; Fu J
Leuk Lymphoma; 2022 Dec; 63(14):3370-3377. PubMed ID: 36239491
[TBL] [Abstract][Full Text] [Related]
2. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
Schmitz R; Wright GW; Huang DW; Johnson CA; Phelan JD; Wang JQ; Roulland S; Kasbekar M; Young RM; Shaffer AL; Hodson DJ; Xiao W; Yu X; Yang Y; Zhao H; Xu W; Liu X; Zhou B; Du W; Chan WC; Jaffe ES; Gascoyne RD; Connors JM; Campo E; Lopez-Guillermo A; Rosenwald A; Ott G; Delabie J; Rimsza LM; Tay Kuang Wei K; Zelenetz AD; Leonard JP; Bartlett NL; Tran B; Shetty J; Zhao Y; Soppet DR; Pittaluga S; Wilson WH; Staudt LM
N Engl J Med; 2018 Apr; 378(15):1396-1407. PubMed ID: 29641966
[TBL] [Abstract][Full Text] [Related]
3. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
Shen R; Fu D; Dong L; Zhang MC; Shi Q; Shi ZY; Cheng S; Wang L; Xu PP; Zhao WL
Signal Transduct Target Ther; 2023 Apr; 8(1):145. PubMed ID: 37032379
[TBL] [Abstract][Full Text] [Related]
4. DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
Akpa CA; Kleo K; Lenze D; Oker E; Dimitrova L; Hummel M
PLoS One; 2019; 14(8):e0220681. PubMed ID: 31419226
[TBL] [Abstract][Full Text] [Related]
5. Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth.
Bujisic B; De Gassart A; Tallant R; Demaria O; Zaffalon L; Chelbi S; Gilliet M; Bertoni F; Martinon F
Blood; 2017 Apr; 129(17):2420-2428. PubMed ID: 28167662
[TBL] [Abstract][Full Text] [Related]
6. Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.
de Groen RAL; van Eijk R; Böhringer S; van Wezel T; Raghoo R; Ruano D; Jansen PM; Briaire-de Bruijn I; de Groot FA; Kleiverda K; Te Boome L; Terpstra V; Levenga H; Nicolae A; Posthuma EFM; Focke-Snieders I; Hardi L; den Hartog WCE; Bohmer LH; Hogendoorn PCW; van den Berg A; Diepstra A; Nijland M; Lugtenburg PJ; Kersten MJ; Pals ST; Veelken H; Bovée JVMG; Cleven AHG; Vermaat JSP
Blood Adv; 2021 Oct; 5(19):3760-3775. PubMed ID: 34478526
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical distinction of ABC and GCB in extranodal DLBCL is not reflected in mutation patterns.
Hallas C; Preukschas M; Tiemann M
Leuk Res; 2019 Jan; 76():107-111. PubMed ID: 30360939
[TBL] [Abstract][Full Text] [Related]
8. Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.
Frauenfeld L; Castrejon-de-Anta N; Ramis-Zaldivar JE; Streich S; Salmerón-Villalobos J; Otto F; Mayer AK; Steinhilber J; Pinyol M; Mankel B; Ramsower C; Bonzheim I; Fend F; Rimsza LM; Salaverria I; Campo E; Balagué O; Quintanilla-Martinez L
Blood Adv; 2022 Apr; 6(7):2361-2372. PubMed ID: 34654055
[TBL] [Abstract][Full Text] [Related]
9. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
[TBL] [Abstract][Full Text] [Related]
10. An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL.
Mai Y; Yu JJ; Bartholdy B; Xu-Monette ZY; Knapp EE; Yuan F; Chen H; Ding BB; Yao Z; Das B; Zou Y; Young KH; Parekh S; Ye BH
Blood; 2016 Dec; 128(24):2797-2807. PubMed ID: 27737889
[TBL] [Abstract][Full Text] [Related]
11. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.
Bohers E; Mareschal S; Bouzelfen A; Marchand V; Ruminy P; Maingonnat C; Ménard AL; Etancelin P; Bertrand P; Dubois S; Alcantara M; Bastard C; Tilly H; Jardin F
Genes Chromosomes Cancer; 2014 Feb; 53(2):144-53. PubMed ID: 24327543
[TBL] [Abstract][Full Text] [Related]
12. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH
Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430
[TBL] [Abstract][Full Text] [Related]
13. Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas.
Lu X; Nechushtan H; Ding F; Rosado MF; Singal R; Alizadeh AA; Lossos IS
Blood; 2005 Apr; 105(7):2924-32. PubMed ID: 15591113
[TBL] [Abstract][Full Text] [Related]
14. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
16. Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?
Barton S; Hawkes EA; Wotherspoon A; Cunningham D
Oncologist; 2012; 17(12):1562-73. PubMed ID: 23086691
[TBL] [Abstract][Full Text] [Related]
17. Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features.
Eriksen PRG; de Groot F; Clasen-Linde E; de Nully Brown P; de Groen R; Melchior LC; Maier AD; Minderman M; Vermaat JSP; von Buchwald C; Pals ST; Heegaard S
Blood Adv; 2024 Apr; 8(8):1946-1957. PubMed ID: 38324724
[TBL] [Abstract][Full Text] [Related]
18. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.
Morin RD; Johnson NA; Severson TM; Mungall AJ; An J; Goya R; Paul JE; Boyle M; Woolcock BW; Kuchenbauer F; Yap D; Humphries RK; Griffith OL; Shah S; Zhu H; Kimbara M; Shashkin P; Charlot JF; Tcherpakov M; Corbett R; Tam A; Varhol R; Smailus D; Moksa M; Zhao Y; Delaney A; Qian H; Birol I; Schein J; Moore R; Holt R; Horsman DE; Connors JM; Jones S; Aparicio S; Hirst M; Gascoyne RD; Marra MA
Nat Genet; 2010 Feb; 42(2):181-5. PubMed ID: 20081860
[TBL] [Abstract][Full Text] [Related]
19. ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?
Nowakowski GS; Czuczman MS
Am Soc Clin Oncol Educ Book; 2015; ():e449-57. PubMed ID: 25993209
[TBL] [Abstract][Full Text] [Related]
20. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.
Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S
Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
